CNS Drugs

, Volume 25, Issue 3, pp 213–226

Managing Cognitive Dysfunction through the Continuum of Alzheimer’s Disease

Role of Pharmacotherapy
  • Julien Delrieu
  • Antoine Piau
  • Céline Caillaud
  • Thierry Voisin
  • Bruno Vellas
Review Article


It has been shown that, during several years preceding the diagnosis of Alzheimer’s disease there is a gradual cognitive decline with a continuum between the pre-dementia stage (still known as the prodromal stage but now included within the general concept of mild cognitive impairment [MCI]) and the other stages of the disease. In MCI, the use of cholinesterase inhibitors (ChEIs) is not associated with any delay in the onset of Alzheimer’s disease or dementia.

During the dementia stages, the three ChEIs (donepezil, galantamine and rivastigmine) are efficacious for mild to moderate Alzheimer’s disease; therefore, monotherapy with a ChEI can be envisaged as initial treatment. Confirmation of the efficacy of ChEIs in the mild dementia stage is essentially based on the results from a single, randomized study carried out specifically among patients at this stage of severity. Memantine can represent an alternative to ChEIs in the moderate stage of Alzheimer’s disease. At the severe stage of the disease, memantine and donepezil are currently indicated. Indeed, memantine has been approved by numerous drug regulatory agencies for use in severe stages of the disease, whereas donepezil has only been approved by the US FDA. There is currently insufficient evidence for recommending combination therapy in Alzheimer’s disease.


  1. 1.
    Amieva H, Jacqmin-Gadda H, Orgogozo JM, et al. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain 2005; 128 (Pt 5): 1093–101PubMedCrossRefGoogle Scholar
  2. 2.
    Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010; 9(1): 119–28PubMedCrossRefGoogle Scholar
  3. 3.
    Delrieu J, Voisin T, Andrieu S, et al. Mild Alzheimer’s disease: a “position paper”. J Nutr Health Aging 2009; 13(6): 503–19PubMedCrossRefGoogle Scholar
  4. 4.
    Frolich L. The cholinergic pathology in Alzheimer’s disease: discrepancies between clinical experience and pathophysiological findings. J Neural Transm 2002; 109(7–8): 1003–13PubMedGoogle Scholar
  5. 5.
    Molinuevo JL, Llado A, Rami L. Memantine: targeting glutamate excitotoxicity in Alzheimer’s disease and other dementias. Am J Alzheimers Dis Other Demen 2005; 20(2): 77–85PubMedCrossRefGoogle Scholar
  6. 6.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. text rev. Washington, DC: American Psychiatric Association, 2000Google Scholar
  7. 7.
    Organisation mondiale de la sante (OMS). ICD-10: international statistical classification of diseases and related health problems. Based on recommendations of the Tenth Revision Conference, 1989 and adopted by the 43rd World Health Assembly. 10th rev. ed. Geneva: World Health Organisation, 1992Google Scholar
  8. 8.
    Reisberg B, Ferris SH, de Leon MJ. Global Deterioration Scale (GDS). Psychopharmacol Bull 1988; 24(4): 661–3PubMedGoogle Scholar
  9. 9.
    Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 1997; 9 Suppl. 1: 173–6; discussion 177-8CrossRefGoogle Scholar
  10. 10.
    Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3): 189–98PubMedCrossRefGoogle Scholar
  11. 11.
    Vellas B, Gauthier S, Allain H, et al. Consensus statement on dementia of Alzheimer type in the severe stage. J Nutr Health Aging 2005; 9(5): 330–8PubMedGoogle Scholar
  12. 12.
    Panisset M, Roudier M, Saxton J, et al. Severe impairment battery: a neuropsychological test for severely demented patients. Arch Neurol 1994 Jan; 51(1): 41–5PubMedCrossRefGoogle Scholar
  13. 13.
    Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006; (1): CD005593Google Scholar
  14. 14.
    McShane R, Schneider LS. Meta-analysis of memantine: summary and commentary on the Cochrane Collaboration’s systematic review. Alzheimers Dement 2005; 1(1): 67–71PubMedCrossRefGoogle Scholar
  15. 15.
    Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981 Aug; 10(2): 122–6PubMedCrossRefGoogle Scholar
  16. 16.
    Giacobini E. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer’s disease? Drugs Aging 2001; 18(12): 891–8PubMedCrossRefGoogle Scholar
  17. 17.
    Lilienfeld S. Galantamine: a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev 2002; 8(2): 159–76PubMedCrossRefGoogle Scholar
  18. 18.
    Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer’s disease. Neurologia 2000 Mar; 15(3): 93–101PubMedGoogle Scholar
  19. 19.
    Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004; 63(4): 651–7PubMedCrossRefGoogle Scholar
  20. 20.
    Koontz J, Baskys A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. Am J Alzheimers Dis Other Demen 2005; 20(5): 295–302PubMedCrossRefGoogle Scholar
  21. 21.
    FeldmanH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6(6): 501–12PubMedCrossRefGoogle Scholar
  22. 22.
    Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008; 70(22): 2024–35PubMedCrossRefGoogle Scholar
  23. 23.
    Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352(23): 2379–88PubMedCrossRefGoogle Scholar
  24. 24.
    Raschetti R, Albanese E, Vanacore N, et al. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 2007; 4(11): e338PubMedCrossRefGoogle Scholar
  25. 25.
    Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry 2006; 77(4): 429–38PubMedCrossRefGoogle Scholar
  26. 26.
    Seltzer B, Zolnouni P, Nunez M, et al., Donepezil 402 Study Group. Efficacy of donepezil in early-stage Alzheimer disease. Arch Neurol 2004; 61: 1852–6PubMedCrossRefGoogle Scholar
  27. 27.
    Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin 2005;21(8): 1317–27PubMedCrossRefGoogle Scholar
  28. 28.
    Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58(3): 427–33PubMedCrossRefGoogle Scholar
  29. 29.
    Burns A, Rossor M, Hecker J, et al., International Donepezil Study Group. The effects of donepezil in Alzheimer’s disease: results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10(3): 237–44PubMedCrossRefGoogle Scholar
  30. 30.
    Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on caregiver burden. J Am Geriatr Soc 2003; 51(6): 737–44PubMedCrossRefGoogle Scholar
  31. 31.
    Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57(3): 489–95PubMedCrossRefGoogle Scholar
  32. 32.
    Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 2001; 49(12): 1590–9PubMedCrossRefGoogle Scholar
  33. 33.
    Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321(7274): 1445–9Google Scholar
  34. 34.
    Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54(12): 2261–8Google Scholar
  35. 35.
    Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD: the Galantamine USA-10 Study Group. Neurology 2000; 54(12): 2269–76PubMedCrossRefGoogle Scholar
  36. 36.
    Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318(7184): 633–8PubMedCrossRefGoogle Scholar
  37. 37.
    Farlow MR, Hake A, Messina J, et al. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001; 58(3): 417–22PubMedCrossRefGoogle Scholar
  38. 38.
    Doraiswamy PM, Krishnan KR, Anand R, et al. Long-term effects of rivastigmine in moderately severe Alzheimer’s disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(4): 705–12PubMedCrossRefGoogle Scholar
  39. 39.
    Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56(9): 1143–53Google Scholar
  40. 40.
    Connelly PJ, James R. SIGN guideline for the management of patients with dementia. Int J Geriatr Psychiatry 2006; 21(1): 14–6PubMedCrossRefGoogle Scholar
  41. 41.
    Day M. NICE says anti-dementia drugs should be used only for moderate Alzheimer’s disease. BMJ 2006; 333(7572): 774PubMedCrossRefGoogle Scholar
  42. 42.
    National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease (update 26 August 2009) [online]. Available from URL: [Accessed 2010 Dec 6]
  43. 43.
    Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007; 14(1): e1–26PubMedCrossRefGoogle Scholar
  44. 44.
    Haute autorité de santé (HAS). Quelle place pour les médicaments anti-Alzheimer dans la prise en charge des patients? [online]. Available from URL: [Accessed 2010 Dec 6]
  45. 45.
    Wallin AK, Hansson O, Blennow K, et al. Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer’s disease? Int J Geriatr Psychiatry 2009; 24(6): 638–47PubMedCrossRefGoogle Scholar
  46. 46.
    Connelly PJ, Prentice NP, Fowler KG. Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2005; 76(3): 320–4PubMedCrossRefGoogle Scholar
  47. 47.
    Hongo J, Nakaaki S, Shinagawa Y, et al. SPECT-identified neuroanatomical predictor of the cognitive effects of donepezil treatment in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2008; 26(6): 556–66PubMedCrossRefGoogle Scholar
  48. 48.
    Kanetaka H, Hanyu H, Hirao K, et al. Prediction of response to donepezil in Alzheimer’s disease: combined MRI analysis of the substantia innominata and SPECT measurement of cerebral perfusion. Nucl Med Commun 2008; 29(6): 568–73PubMedCrossRefGoogle Scholar
  49. 49.
    Csernansky JG, Wang L, Miller JP, et al. Neuroanatomical predictors of response to donepezil therapy in patients with dementia. Arch Neurol 2005; 62(11): 1718–22PubMedCrossRefGoogle Scholar
  50. 50.
    Scacchi R, Gambina G, Moretto G, et al. Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer’s disease and relationships with response to treatment with donepezil and rivastigmine. Am J Med Genet B Neuropsychiatr Genet 2009; 150B(4): 502–7PubMedCrossRefGoogle Scholar
  51. 51.
    Emre M, Qizilbash N. Experimental approaches and drug in development for the treatment of dementia. Expert Opin Investig Drugs 2001; 10(4): 607–17PubMedCrossRefGoogle Scholar
  52. 52.
    Cacabelos R, Takeda M, Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer’s disease. Int J Geriatr Psychiatry 1999; 14: 3–47PubMedCrossRefGoogle Scholar
  53. 53.
    Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system: too little activation is bad, too much is even worse. Neuropharmacology 2007; 53: 699–723PubMedCrossRefGoogle Scholar
  54. 54.
    Möbius HJ. Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alzheimer Dis Assoc Disord 1999; 13 Suppl. 3: S172–8PubMedCrossRefGoogle Scholar
  55. 55.
    Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003; 348(14): 1333–41PubMedCrossRefGoogle Scholar
  56. 56.
    Peterson L. Trends-in-medicine: American Neurological Association, November 2003 [online]. Available from URL: [Accessed 2010 Nov 22]
  57. 57.
    Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291(3): 317–24PubMedCrossRefGoogle Scholar
  58. 58.
    Peskind ER, Potkin SG, Pomara N. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006; 14(8): 704–15PubMedCrossRefGoogle Scholar
  59. 59.
    Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2008 Feb; 13(1): 97–107PubMedGoogle Scholar
  60. 60.
    Doody RS, Tariot PN, Pfeiffer E, et al. Meta-analysis of six month memantine clinical trials. New Clinical Drug Evaluation Unit 45 Annual Meeting; 2005 Jun 6–9; Boca Raton (FL)Google Scholar
  61. 61.
    Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379–97PubMedGoogle Scholar
  62. 62.
    van Dyck CH, Tariot PN, Meyers B, et al. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007 Apr–Jun; 21(2): 136–43PubMedCrossRefGoogle Scholar
  63. 63.
    Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008 Feb; 5(1): 83–9PubMedCrossRefGoogle Scholar
  64. 64.
    Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351(24): 2509–18PubMedCrossRefGoogle Scholar
  65. 65.
    McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigminein dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356(9247): 2031–6PubMedCrossRefGoogle Scholar
  66. 66.
    Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8(7): 613–8PubMedCrossRefGoogle Scholar
  67. 67.
    Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20(2 Suppl. 1): S12–8PubMedCrossRefGoogle Scholar
  68. 68.
    Mori E, Hashimoto M, Krishnan KR, et al. What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors? Alzheimer Dis Assoc Disord 2006; 20(2 Suppl. 1): S19–26PubMedCrossRefGoogle Scholar
  69. 69.
    Hashimoto M, Kazui H, Matsumoto K, et al. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer’s disease? Am J Psychiatry 2005; 162(4): 676–82PubMedCrossRefGoogle Scholar
  70. 70.
    Mangialasche F, Solomon A, Winblad B, et al. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol 2010; 9(7): 702–16PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Julien Delrieu
    • 1
    • 2
  • Antoine Piau
    • 1
  • Céline Caillaud
    • 1
  • Thierry Voisin
    • 1
    • 2
  • Bruno Vellas
    • 1
    • 2
  1. 1.Alzheimer’s Disease Clinical Research Centre, GérontopôleToulouse University HospitalToulouse cedexFrance
  2. 2.INSERM U558ToulouseFrance

Personalised recommendations